Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Front Immunol · 2014 · PMC4018526 · PMID 24834066

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

showed a trend of superior treatment outcome of sipuleucel-T in patients in the lowest PSA-level quartile (≤22.1 ng/mL).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.